Notice: This company has been marked as potentially delisted and may not be actively trading. Cyclacel Pharmaceuticals (CYCCP) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsDividendHeadlinesTrends CYCCP vs. ATNFW, SXTPW, DRTSW, WENAW, APLMW, BCTXW, CDIOW, CTCXW, CELUW, and CEROWShould you be buying Cyclacel Pharmaceuticals stock or one of its competitors? The main competitors of Cyclacel Pharmaceuticals include 180 Life Sciences (ATNFW), 60 Degrees Pharmaceuticals (SXTPW), Alpha Tau Medical (DRTSW), Anew Medical (WENAW), Apollomics (APLMW), BriaCell Therapeutics (BCTXW), Cardio Diagnostics (CDIOW), Carmell (CTCXW), Celularity (CELUW), and CERo Therapeutics (CEROW). These companies are all part of the "biotechnology" industry. Cyclacel Pharmaceuticals vs. 180 Life Sciences 60 Degrees Pharmaceuticals Alpha Tau Medical Anew Medical Apollomics BriaCell Therapeutics Cardio Diagnostics Carmell Celularity CERo Therapeutics 180 Life Sciences (NASDAQ:ATNFW) and Cyclacel Pharmaceuticals (NASDAQ:CYCCP) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, community ranking, media sentiment, profitability, analyst recommendations, risk, institutional ownership and dividends. Does the MarketBeat Community favor ATNFW or CYCCP? Cyclacel Pharmaceuticals received 97 more outperform votes than 180 Life Sciences when rated by MarketBeat users. CompanyUnderperformOutperform180 Life SciencesN/AN/ACyclacel PharmaceuticalsOutperform Votes9767.36% Underperform Votes4732.64% Does the media favor ATNFW or CYCCP? In the previous week, 180 Life Sciences and 180 Life Sciences both had 1 articles in the media. 180 Life Sciences' average media sentiment score of 1.38 beat Cyclacel Pharmaceuticals' score of 0.00 indicating that 180 Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 180 Life Sciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cyclacel Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is ATNFW or CYCCP more profitable? Company Net Margins Return on Equity Return on Assets 180 Life SciencesN/A N/A N/A Cyclacel Pharmaceuticals N/A N/A N/A Which has stronger earnings & valuation, ATNFW or CYCCP? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio180 Life SciencesN/AN/AN/AN/AN/ACyclacel PharmaceuticalsN/AN/AN/AN/AN/A Summary180 Life Sciences and Cyclacel Pharmaceuticals tied by winning 1 of the 2 factors compared between the two stocks. Get Cyclacel Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CYCCP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYCCP vs. The Competition Export to ExcelMetricCyclacel PharmaceuticalsBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$117.40M$5.83B$8.91BDividend Yield0.12%3.69%4.75%3.85%P/E RatioN/A3.2126.7719.24Price / SalesN/A4,796.44421.6566.67Price / CashN/A13.0138.0134.83Price / BookN/A48.067.674.58Net IncomeN/A-$87.82M$3.19B$245.77M Cyclacel Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYCCPCyclacel PharmaceuticalsN/A$8.59+30.2%N/AN/A$0.00N/A0.0012ATNFW180 Life SciencesN/A$0.01+6.5%N/A+9.9%$0.00N/A0.007Gap DownSXTPW60 Degrees PharmaceuticalsN/A$0.03flatN/A-67.7%$0.00$502,409.000.002Gap DownDRTSWAlpha Tau MedicalN/A$0.35+16.7%N/A+0.0%$0.00N/A0.0080News CoverageGap DownWENAWAnew MedicalN/A$0.04-0.3%N/AN/A$0.00N/A0.00N/AGap DownAPLMWApollomicsN/A$0.01+9.1%N/A-55.5%$0.00N/A0.0059Positive NewsGap UpBCTXWBriaCell TherapeuticsN/A$0.12flatN/A-92.4%$0.00N/A0.008Gap DownCDIOWCardio DiagnosticsN/A$0.07-4.7%N/A-56.6%$0.00$35,688.000.007Gap UpCTCXWCarmellN/A$0.04+59.4%N/AN/A$0.00$32,839.000.0014Gap UpCELUWCelularityN/A$0.06+0.2%N/AN/A$0.00$48.20M0.00220Gap UpCEROWCERo TherapeuticsN/A$0.02+15.4%N/AN/A$0.00N/A0.008Positive NewsGap Up Related Companies and Tools Related Companies 180 Life Sciences Competitors 60 Degrees Pharmaceuticals Competitors Alpha Tau Medical Competitors Anew Medical Competitors Apollomics Competitors BriaCell Therapeutics Competitors Cardio Diagnostics Competitors Carmell Competitors Celularity Competitors CERo Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CYCCP) was last updated on 2/24/2025 by MarketBeat.com Staff From Our PartnersWhy 2026 will be a disaster for many AmericansWall Street Legend: Why stocks are very likely to crash in Trump's 2nd Year Legendary investor Marc Chaikin...Chaikin Analytics | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThis Crypto Is Set to Explode in FebruaryA little-known IRS loophole has been gaining serious attention... If you have a retirement account, you can...Premier Gold Co | Sponsored$5,000 DOGE check?Elon Musk's DOGE agenda just took a very surprising turn... Earlier this week, reports emerged that a porti...Altimetry | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | SponsoredHas Trump finally met his match?A new Chinese AI software called "DeepSeek" is sending shockwaves through the market. It's advanced enough ...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclacel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclacel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.